1300591-01-8

Upstream product

• 1300590-91-3 2'-O-amino-3',5'-di-O-benzyl-4'-carboxy-5-methyluridine 
• 1300590-93-5 3',5'-di-O-benzyl-4'-carboxy-2'-O-(N-methyleneamino)-5-methyluridine 
• 1300590-95-7 3',5'-di-O-benzyl-4'-carboxy-2'-O-(N-methylamino)-5-methyluridine 
• 1300590-97-9 (1R,5R,6R,8S)-3-aza-8-benzyloxy-1-benzyloxymethyl-3-methyl-6-(thymin-1-yl)-4,7-dioxabicyclo[3.2.1]octan-2-one 
• 1300590-99-1 (1R,5R,6R,8S)-3-aza-8-hydroxy-1-hydroxymethyl-3-methyl-6-(thymin-1-yl)-4,7-dioxabicyclo[3.2.1]octan-2-one 
• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 1300589-63-2 2'-O-acetyl-3',5'-di-O-benzyl-4'-C-(tert-butyldiphenylsilyloxymethyl)-5-methyluridine 
• 1300589-73-4 C₄₂H₄₅F₃N₂O₉SSi 
• 1300589-65-4 3',5'-di-O-benzyl-4'-C-(tert-butyldiphenylsilyloxymethyl)-5-methyluridine 
• 1300589-70-1 3',5'-di-O-benzyl-4'-C-(tert-butyldiphenylsilyloxymethyl)-5-methylarabinouridine 
• 1300590-85-5 3',5'-di-O-benzyl-4'-C-(tert-butyldiphenylsilyloxymethyl)-2'-O-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-5-methyluridine 
• 1300590-87-7 3',5'-di-O-benzyl-2'-O-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-4'-C-hydroxymethyl-5-methyluridine 
• 1300589-67-6 C₄₁H₄₄N₂O₆Si 
• 1300589-59-6 C₄₀H₄₆O₈Si 

Downstream Products

• 1300591-03-0 (1R,5R,6R,8S)-3-aza-8-(2-cyanoethoxy(diisopropylamino)-phosphinoxy)-1-(4,4'-dimethoxytrityloxymethyl)-3-methyl-6-(thymin-1-yl)-4,7-dioxabicyclo[3.2.1]octan-2-one 

Relevant academic research and scientific papers

BRIDGED ARTIFICIAL NUCLEOSIDE AND NUCLEOTIDE

It is an object of the present invention to provide a novel molecule for antisense therapies which is not susceptible to nuclease degradation in vivo and has a high binding affinity and specificity for the target mRNAs and which can efficiently regulate expression of specific genes. The novel artificial nucleoside of the present invention has an amide bond introduced into a bridge structure of 2′,4′-BNA/LNA. The oligonucleotide containing the 2′,4′-bridged artificial nucleotide has a binding affinity for a single-stranded RNA comparable to known 2′,4′-BNA/LNA and has an increased nuclease resistance over LNA. Particularly, it is expected to be applied to nucleic acid drugs because of its much stronger binding affinity for single-stranded RNAs than S-oligo's affinity

Synthesis and properties of a bridged nucleic acid with a perhydro-1,2-oxazin-3-one ring

A novel derivative of 2′,4′-bridged nucleic acid, named hydroxamate-bridged nucleic acid (HxNA), containing a six-membered perhydro-1,2-oxazin-3-one ring, was designed and synthesized. The introduction of a carbonyl function along with an N-O linkage in the six-membered bridged structure is the unique structural feature of the novel 2′,4′- bridged nucleic acid analogue. The design was carried out to restrict the flexibility of the sugar moiety through the trigonal planarity of carbonyl function, which would improve the properties of the modification. The synthesized monomer was incorporated into oligonucleotides, and their properties were examined. The HxNA-modified oligonucleotides exhibited selectively high affinity toward complementary ssRNA. Furthermore, the nuclease resistance of the HxNA-modified oligonucleotide was found to be higher than that of the corresponding natural and 2′,4′-BNA/LNA-modified oligonucleotides. Interestingly, exposure of HxNA modified oligonucleotide to 3′-exonuclease resulted in gradual opening of the bridge, which stopped further digestion. Moreover, ring-opening of only one modification at the 3′-end of the oligonucleotides was observed, even if two or three HxNA modifications were present in the sequence. The results demonstrate the strong potential of the HxNA modification as a switch for the generation of highly nuclease-resistant RNA selective oligonucleotide in situ, which could have potential applications in antisense technology.